Precision BioSciences Inc (DTIL)
Precision BioSciences, Inc. is a clinical-stage biotechnology company focused on gene editing therapies in the United States. The company’s ARCUS genome editing platform is designed to support DNA insertion, removal, and repair, and underpins a development pipeline aimed at in vivo gene editing applications. Its programs include PBGENE-HBV for chronic hepatitis B, PBGENE-DMD (Excision) for Duchenne muscular dystrophy, PBGENE-3243 for m.3243-associated mitochondrial diseases, and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. Precision BioSciences also has collaboration agreements with TG Cell Therapy, Inc. and iECURE, Inc. to advance ARCUS-based gene editing and insertion programs. Incorporated in 2006, the company is headquartered in Durham, North Carolina.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-DTIL
|
$7.10
|
-4.6% Downside
|
Fair
|
$29.60
|
297.8% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-4.4x
|
2.6x
|
4.3x
|
189.9 M
|
122.1 M
|
13.0%
|
77.5%
|
-3.4
|
—
|
132.1%
|
